USLU, S. Et Al. 2022. The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort. ARTHRITIS & RHEUMATOLOGY , 847-849.

USLU, S., GÜLLE, S., CAN, G., Senel, S., ÇAPAR, S., DALKILIÇ, H. E., ... AKAR, S.(2022). The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort. ARTHRITIS & RHEUMATOLOGY , 847-849.

USLU, SADETTİN Et Al. "The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort," ARTHRITIS & RHEUMATOLOGY , 847-849, 2022

USLU, SADETTİN Et Al. "The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort." ARTHRITIS & RHEUMATOLOGY , pp.847-849, 2022

USLU, S. Et Al. (2022) . "The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort." ARTHRITIS & RHEUMATOLOGY , pp.847-849.

@article{article, author={SADETTİN USLU Et Al. }, title={The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort}, journal={ARTHRITIS & RHEUMATOLOGY}, year=2022, pages={847-849} }